Mitochondrial deoxynucleoside triphosphates are formed and regulated by a network of anabolic and catabolic enzymes present both in mitochondria and the cytosol. Genetic deficiencies for enzymes of the network cause mitochondrial DNA depletion and disease. We investigate by isotope flow experiments the interrelation between mitochondrial and cytosolic deoxynucleotide pools as well as the contributions of the individual enzymes of the network to their maintenance. To study specifically the synthesis of dGTP used for the synthesis of mitochondrial and nuclear DNA, we labeled hamster CHO cells or human fibroblasts with [ 3 H]deoxyguanosine during growth and quiescence and after inhibition with aphidicolin or hydroxyurea. At time intervals we determined the labeling of deoxyguanosine nucleotides and DNA and the turnover of dGTP from its specific radioactivity in the separated mitochondrial and cytosolic pools. In both cycling and quiescent cells, the import of deoxynucleotides formed by cytosolic ribonucleotide reductase accounted for most of the synthesis of mitochondrial dGTP, with minor contributions by cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. A dynamic isotopic equilibrium arose rapidly from the shuttling of deoxynucleotides between mitochondria and cytosol, incorporation of dGTP into DNA, and degradation of dGMP. Inhibition of DNA synthesis by aphidicolin marginally affected the equilibrium. Inhibition of DNA synthesis by blockage of ribonucleotide reduction with hydroxyurea instead disturbed the equilibrium and led to accumulation of labeled dGTP in the cytosol. The turnover of dGTP decreased, suggesting a close connection between ribonucleotide reduction and pool degradation.
Mitochondrial (mt)2 deoxynucleotides are formed and regulated by a network of anabolic and catabolic enzymes located in both the cytosol and mitochondria. The enzymes are of considerable medical interest. Many drugs used in cancer and virus therapy are deoxynucleoside analogs whose activity requires phosphorylation by kinases (1) and whose efficacy and toxicity is affected by the interplay between the enzymes in the network. The enzymes may also be involved in oxidative damage by activating modified bases such as 8-oxoguanine for incorporation into RNA and DNA (2). Moreover, an increasing number of diseases with depletion of mt DNA arise from genetic deficiency of enzymes in the network (3). In some cases the genetic deficiency leads to depletion of mt deoxyribonucleoside triphosphate (dNTP) (4 -6), in other cases to overproduction (7-9). In both instances the disturbed normal balance between the four dNTPs results in disease. Early examples are the catabolic phosphorylases that degrade purine (7) or thymine nucleosides (9). Their loss causes overproduction of dGTP or dTTP, with the affected individuals suffering from immune deficiency (7,8) or mitochondrial neurogastrointestinal encephalomyopathy (9), respectively. Later discovered examples are the anabolic mt salvage enzymes deoxyguanosine kinase (dGK) (4...